Company Overview and News
Minbos Resources Ltd's (ASX:MNB) shares have entered pre-open following the ASX granting the company a trading halt.
Minbos (ASX:MNB) has been granted a trading halt by the ASX, pending a merger update with its joint venture partners. The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.
LONDON, UNITED KINGDOM--(Marketwired - March 6, 2017) - Horizonte Minerals Plc, (AIM:HZM)(TSX:HZM) ('Horizonte' or 'the Company') the nickel development company focused in Brazil, is pleased to announce that it has completed the tender process and has awarded the contracts for the Feasibility Study ('FS') for its 100%-owned Araguaia nickel project ('Araguaia' or 'the Project').
6 March 2017 - Horizonte Minerals Plc, (AIM: HZM, TSX: HZM) ('Horizonte' or 'the Company') the nickel development company focused in Brazil, is pleased to announce that it has completed the tender process and has awarded the contracts for the Feasibility Study ('FS') for its 100%-owned Araguaia nickel project ('Araguaia' or 'the Project').
Harvest One Capital Inc. (NEX:WON.H) ("Harvest One" or the "Company") announces that it has appointed a syndicate of agents led by Mackie Research Capital Corporation (as the "Lead Agent" and sole bookrunner) and including Canaccord Genuity Corp., Dundee Capital Partners Limited, and GMP Securities L.P. (collectively, the "Agents") to sell by way of a private placement a minimum of 20,000,000 subscription receipts (the "Subscription Receipts") at a price of $0.
Phosphate explorer Minbos Resources has entered into a new agreement to merge with joint venture partner Petril Phosphate, in a scrip and royalties deal valued at about $20 million.
The halt will remain in place until the opening of trade on Tuesday 6th December 2016, or earlier if an announcement is made to the market.
Minbos Resources Ltd (ASX:MNB) is focused on exploration and development of phosphate ore within the Cabinda Province of Angola.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...